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Background
Current in vitro and animal tests for drug development
are failing to emulate the organ complexity of the
human body and, therefore, to accurately predict drug
toxicity. In this study, we present a self-contained, bior-
eactor based human in vitro tissue culture test system
aiming to support predictive substance testing at rele-
vant throughput. We designed a microcirculation system
interconnecting several tissue culture spaces within a
PDMS-embedded microfluidic channel circuit. The bior-
eactor is reproducibly perfused by a peristaltic on-chip
micro-pump, providing a near physiologic fluid flow and
volume to liquid ratio.
Materials and methods
Liver microtissue aggregates containing 4.8 × 104
HepaRG cells and 0.2 × 104 human hepatic stellate cells
(HHSteC) were formed in Perfecta3D® 384-Well Hang-
ing Drop Plates (3D Biomatrix, USA). After two days of
hanging drop culture, 20 aggregates were loaded into a
single tissue culture compartment of the micro-bioreac-
tor. Each circuit of the micro-bioreactor device con-
tained 700 μl medium in total. During the first 7 days, a
40% media exchange rate was applied at 12 h intervals.
From day 8 onwards, a 40% exchange rate was applied
at 24 h intervals. Daily samples were collected for
respective analyses. Experiments were stopped at day 14
and 28 and tissues were subjected to immunohisto-
chemical stainings and qRT-PCR analyses. Experiments
were conducted with four replicates. To expose the
chip-cultures to troglitazone, liver microtissues were
cultured for one day in normal medium and were, sub-
sequently, treated with 0 μM, 5 μM and 50 μM sub-
stance, respectively. Application of troglitazone was
repeated at 12 h or 24 h intervals simultaneously with
the medium change.
Results
Cultures of human artificial liver microtissues have suc-
cessfully been cultivated over 28 days in the novel micro-
fluidic bioreactor. Glucose consumption and lactate
production indicated an aerobic metabolism which
reached a steady state after 7 days. Immunohistochemical
staining revealed the expression of phase I metabolic
enzymes CYP450 3A4 and CYP450 7A1, extracellular
matrix component collagen I, apical transporter MRP2
and tight junction protein ZO-1 (Figure 1A-D). Cell viabi-
lity over 28 days was increased in the bioreactor culture
compared to static control (Figure 1E, F). Furthermore,
the cultures revealed a dose-dependent response to a
7-day exposure to the toxic substance troglitazone. Liver
microtissues showed sensitivity at different molecular
levels. Concentration of LDH released to the medium
increased with troglitazone concentration and gene
expression of selected marker genes varied. An induction
of CYP450 3A4 by troglitazone treatment was also
recorded on protein level by immunhistochemistry.
Conclusion
A promising tool for long term culture of human liver
equivalents has been developed. The simple MOC design
presented, assisted the culture of human liver equivalents
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over a period of up to 28 days. The cultures, operated at
a total on-chip volume of 700 μl medium at recirculation
rates of 40 μl/min assisted by an on-chip micropump,
stabilize approximately within a week at a metabolic
steady state. The prediction of toxicology profiles of com-
pounds metabolised by the liver was demonstrated possi-
ble by exposing the cells to different concentrations of
troglitazone. This platform is designed to generate high-
quality in vitro data predictive of substance safety in
humans. Tissue cultures can be exposed to pharmaceuti-
cal substances at regimens relevant to respective guide-
lines, currently used for subsystemic substance testing in
animals.
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Figure 1 14-day tissue performance of the micro-bioreactor culture compared to static control Cell functionality shown by
immunostaining of (A) phase I enzyme CYP450 3A4 (red) and CYP450 7A1 (green), (B) collagen I (red) and vimentin (green), (C)
MRP2, an ABC transporter located at the apical membrane, (green) and (D) tight junction protein ZO-1 (red). Cell viability shown by
TUNEL KI67 staining of (E) liver equivalents cultivated for 28 days in the micro-bioreactor and (F) liver equivalents cultivated for 28 days under
static conditions. Nuclei are stained with hoechst 33342. Scale bar: 100 μm.
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